Analysts think NERV stock price could increase by 122%
Jul 31, 2024, 6:26 AM
-14.29%
What does NERV do
Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for CNS diseases, with leading candidates roluperidone for schizophrenia and MIN-301 for Parkinson's. Established in 2014, the company also advances seltorexant for insomnia and MDD while employing nine full-time staff.
3 analysts think NERV stock price will increase by 121.74%. The current median analyst target is $7.14 compared to a current stock price of $3.22. The lowest analysts target is $7.07 and the highest analyst target is $7.35.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
